CA2321728C - Epiallopregnanolone in the treatment of cns disorders - Google Patents

Epiallopregnanolone in the treatment of cns disorders Download PDF

Info

Publication number
CA2321728C
CA2321728C CA002321728A CA2321728A CA2321728C CA 2321728 C CA2321728 C CA 2321728C CA 002321728 A CA002321728 A CA 002321728A CA 2321728 A CA2321728 A CA 2321728A CA 2321728 C CA2321728 C CA 2321728C
Authority
CA
Canada
Prior art keywords
hydroxy
5alpha
pregnan
3beta
steroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002321728A
Other languages
English (en)
French (fr)
Other versions
CA2321728A1 (en
Inventor
Torbjorn Backstrom
Ming-De Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Umecrine Mood AB
Original Assignee
Umecrine AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine AB filed Critical Umecrine AB
Publication of CA2321728A1 publication Critical patent/CA2321728A1/en
Application granted granted Critical
Publication of CA2321728C publication Critical patent/CA2321728C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002321728A 1998-03-11 1999-03-10 Epiallopregnanolone in the treatment of cns disorders Expired - Fee Related CA2321728C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3786998A 1998-03-11 1998-03-11
US09/037,869 1998-03-11
PCT/EP1999/001496 WO1999045931A1 (en) 1998-03-11 1999-03-10 Epiallopregnanolone in the treatment of cns disorders

Publications (2)

Publication Number Publication Date
CA2321728A1 CA2321728A1 (en) 1999-09-16
CA2321728C true CA2321728C (en) 2008-12-09

Family

ID=21896803

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002321728A Expired - Fee Related CA2321728C (en) 1998-03-11 1999-03-10 Epiallopregnanolone in the treatment of cns disorders

Country Status (9)

Country Link
US (1) US6455516B1 (cg-RX-API-DMAC7.html)
EP (1) EP1063999B1 (cg-RX-API-DMAC7.html)
JP (1) JP3877961B2 (cg-RX-API-DMAC7.html)
CN (1) CN1270718C (cg-RX-API-DMAC7.html)
AT (1) ATE307592T1 (cg-RX-API-DMAC7.html)
AU (1) AU756001B2 (cg-RX-API-DMAC7.html)
CA (1) CA2321728C (cg-RX-API-DMAC7.html)
DE (1) DE69927960T2 (cg-RX-API-DMAC7.html)
WO (1) WO1999045931A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
DK1812009T3 (da) * 2004-11-18 2013-08-05 Umecrine Ab GABA-steroidantagonister og deres anvendelse til behandling af CNS-lidelser
RU2413516C2 (ru) * 2004-11-18 2011-03-10 Умекрин Аб Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
EP2711372A1 (en) 2006-11-21 2014-03-26 Umecrine AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders
EP2167098B1 (en) * 2007-06-11 2018-09-05 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
US20100204192A1 (en) 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
JP5687287B2 (ja) * 2010-01-14 2015-03-18 ウメクライン ムード エービー 改善された保存性及び溶解特性を有する3−ベータ−ヒドロキシ−5−アルファ−プレグナン−20−オンを含有する薬学的組成物
CN106983754A (zh) 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
RU2667065C2 (ru) 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
US20150313915A1 (en) * 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
CN106163528A (zh) 2014-01-29 2016-11-23 梅克芳识别有限公司 用于治疗肝脑病的甾族化合物
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) * 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ab公司 新穎化合物
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
US10933014B2 (en) 2017-01-09 2021-03-02 Asarina Pharma Ab Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
CN110430883A (zh) 2017-02-10 2019-11-08 阿沙里那制药公司 用于医学治疗的3β-羟基-5α-孕烷-20-酮
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
US20210228596A1 (en) * 2017-10-12 2021-07-29 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
CN111918657A (zh) 2018-04-05 2020-11-10 阿沙里那制药有限公司 用于治疗物质戒断障碍的gaba-a拮抗剂
US20240383942A1 (en) 2021-09-14 2024-11-21 Nanjing Minova Pharmaceutical Co., Ltd. Water-soluble allopregnanolone derivative, and preparation method therefor and use thereof
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083979A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
CN1254283A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 孕烷-3-醇-20-酮

Also Published As

Publication number Publication date
DE69927960T2 (de) 2006-07-20
WO1999045931A1 (en) 1999-09-16
EP1063999B1 (en) 2005-10-26
EP1063999A1 (en) 2001-01-03
CN1270718C (zh) 2006-08-23
US6455516B1 (en) 2002-09-24
CN1300219A (zh) 2001-06-20
JP2002506034A (ja) 2002-02-26
AU3329299A (en) 1999-09-27
DE69927960D1 (de) 2005-12-01
ATE307592T1 (de) 2005-11-15
AU756001B2 (en) 2003-01-02
JP3877961B2 (ja) 2007-02-07
CA2321728A1 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
AU756001B2 (en) Epiallopregnanolone in the treatment of CNS disorders
US8119619B2 (en) Pregnane steroids and their use in the treatment of CNS disorders
US8372824B2 (en) GABA-steroid antagonists and their use for the treatment of CNS disorders
CN1254283A (zh) 孕烷-3-醇-20-酮
BR112020019538A2 (pt) Antagonistas gaba-a para tratar transtornos por abstinência de substância
JP2001513800A (ja) 医薬組成物調製のためのピバガビンの使用
AU642520B2 (en) Therapeutic use of piperidine-2,6-diones
EP1944041A1 (en) Therapeutic agent for neurogenic pain

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190311